Humasis Co

Humasis Co Treasury Stock

The Treasury Stock of Humasis Co (205470.KQ) as of Nov 10, 2026 is 2.01 B KRW. In the previous year, Treasury Stock was 1.44 B KRW — a change of 40.07% (higher).

Treasury Stock

2.01 BKRW

YoY

40.07%

Last updated:

Treasury Stock of Humasis Co is 2024 2.01 B KRW. Treasury Stock of Humasis Co was 2023 1.44 B KRW. It decreases by 40.07% higher compared to the previous year.

The Humasis Co Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2017
96.44 M KRW
Jan 1, 2018
-59.40 M KRW
Jan 1, 2019
-200.00 KRW
Jan 1, 2020
-10.11 M KRW
Jan 1, 2021
2.65 B KRW
Jan 1, 2022
1.26 B KRW
Jan 1, 2023
1.44 B KRW
Jan 1, 2024
2.01 B KRW
The Humasis Co Treasury Stock history
YEARTreasury StockYoY
2.01 BKRW+40.07%
1.44 BKRW+13.76%
1.26 BKRW-52.30%
2.65 BKRW-26,267.47%
-10.11 MKRW+5.06 M%
-200.00KRW-100.00%
-59.40 MKRW-161.58%
96.44 MKRW-57.94%
229.28 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Treasury Stock of Humasis Co is 2.01 B KRW in 2024.

Treasury Stock of Humasis Co changed from 1.44 B KRW to 2.01 B KRW, representing a 40.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Humasis Co

All Key Metrics — Humasis Co